However, in the MSK-IMPACT cohort of our study the PD1/PD-L1 inhibitors seem to improve the clinical outcome of CDKN2A-MUT patients with NSCLC or head and neck cancer, treated by ICIs, in despite of CDKN2A ALT being found to be a risk factor of survival in the MSK-MetTropism and TCGA cohorts. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.